Top pick for
ImmuPharma plc (IMM) is a leading biotechnology business based in the UK. It opened the day at 13.305p after a previous close of 13.25p. During the day the price has varied from a low of 12.6p to a high of 13.65p. The latest price was 12.802p (25 minute delay). ImmuPharma is listed on the London Stock Exchange (LSE) and employs 17 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, ImmuPharma's share price has had significant negative movement.
Its last market close was 14.35p, which is 10.31% down on its pre-crash value of 16p and 104.71% up on the lowest point reached during the March crash when the shares fell as low as 7.01p.
If you had bought £1,000 worth of ImmuPharma shares at the start of February 2020, those shares would have been worth £623.98 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,059.04.
|52-week range||6.91p - 34p|
|50-day moving average||14.7022p|
|200-day moving average||13.6957p|
|Wall St. target price||5p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-5.1p|
Fees apply. Your capital is at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-07-06)||-3.38%|
|1 month (2020-06-12)||-17.54%|
|3 months (2020-04-09)||26.44%|
|6 months (2020-01-13)||-18.20%|
|1 year (2019-07-12)||25.05%|
|2 years (2018-07-13)||-41.28%|
|3 years (2017-07-13)||-77.93%|
|5 years (2015-07-13)||-67.38%|
|Gross profit TTM||£77,925|
|Return on assets TTM||-54.31%|
|Return on equity TTM||-95%|
|Market capitalisation||£25.3 million|
TTM: trailing 12 months
We're not expecting ImmuPharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, ImmuPharma's shares have ranged in value from as little as 6.91p up to 34p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while ImmuPharma's is 0.6529. This would suggest that ImmuPharma's shares are less volatile than average (for this exchange).
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.